Monlunabant治疗肥胖与代谢综合征的2a期试验
这项16周、双盲、随机、安慰剂对照的2a期剂量探索试验在加拿大25个门诊研究中心纳入肥胖合并代谢综合征成人,按1:1:1:1随机接受monlunabant 10 mg、20 mg、50 mg或安慰剂每日一次口服。第16周时各剂量组体重较基线下降均显著优于安慰剂,不良事件多为轻中度胃肠道及精神类,因不良事件退出呈剂量依赖性。
要点
- 不良事件多为轻中度胃肠道和精神类,因不良事件退出随剂量升高而增多。
- 研究者认为需进一步评估更低剂量monlunabant的安全性与疗效。
核心结论
- 所有测试剂量的monlunabant均较安慰剂带来有统计学显著和临床意义的体重下降。
- 更高剂量仅带来略大的体重下降,而不良事件呈剂量依赖性。
- 需进一步研究评估更低剂量的安全性和疗效,以评价其作为肥胖治疗药物的潜力。
研究设计与样本
- 16周、随机、双盲、安慰剂对照、剂量探索2a期试验,在加拿大25个门诊研究中心开展。
- 纳入肥胖合并代谢综合征成人,按1:1:1:1随机分配至monlunabant 10 mg、20 mg、50 mg或安慰剂每日一次口服。
- 共243例被随机分配:10 mg组61例、20 mg组61例、50 mg组60例、安慰剂组61例;242例接受治疗,其中女性167例(69%)、男性75例(31%)。
- 183例(76%)完成试验:10 mg组50/61(82%)、20 mg组42/60(70%)、50 mg组34/60(57%)、安慰剂组57/61(93%)。
- 主要终点为第16周体重(kg)较基线变化与安慰剂的比较,采用重复测量混合模型分析。
主要发现
- 不良事件总体多为轻中度胃肠道和精神类疾病:10 mg组42/61(69%)、20 mg组47/60(78%)、50 mg组55/60(92%)、安慰剂组42/61(69%)。
- 因不良事件退出呈剂量依赖性:10 mg组8/61(13%)、20 mg组16/60(27%)、50 mg组25/60(42%)、安慰剂组0例,主要驱动因素为恶心、焦虑、腹泻、易激惹和睡眠障碍。
- 未报告死亡。
关键数值与推荐
- 主要终点为第16周体重(kg)较基线变化与安慰剂比较。
- 主要估计目标采用重复测量混合模型分析,假设缺失数据为随机缺失。
- 安全性分析纳入所有接受至少一剂试验产品的随机参与者。
临床怎么用
- monlunabant各测试剂量均可带来较安慰剂显著的体重下降,但剂量升高时不良事件和因不良事件退出增加。
- 临床应用需权衡体重获益与胃肠道及精神类不良事件风险,尤其在高剂量时。
- 研究提示需进一步评估更低剂量方案的安全性与疗效。
局限性
- 研究为16周2a期剂量探索试验,样本量243例,完成率随剂量升高而下降(50 mg组57%)。
- 因不良事件退出呈剂量依赖性,可能影响高剂量组结果的解释。
- 研究者指出需进一步研究评估更低剂量的安全性和疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Monlunabant, a novel cannabinoid receptor 1 (CB1R) inverse agonist, has shown encouraging weight loss efficacy and tolerability. We aimed to evaluate the efficacy and safety of monlunabant in individuals with obesity and metabolic syndrome. METHODS: This 16-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2a trial, conducted at 25 outpatient research centres in Canada, enrolled adults with obesity and metabolic syndrome. Participants were randomly assigned (1:1:1:1) by means of an interactive response system to once-daily oral tablets of monlunabant 10 mg, 20 mg, 50 mg, or placebo. The participants, site staff, sponsor, and contract research organisation were masked to treatment allocation. The primary endpoint was mean bodyweight (kg) change from baseline at week 16 versus placebo, assessed in all eligible randomised participants, whereas the safety analysis was done in all randomised participants who received at least one dose of trial product. The estimator for the primary estimand was analysed using a mixed model for repeated measures, assuming missing data are missing at random. This trial is registered with ClinicalTrials.gov (NCT05891834) and is complete. FINDINGS: From Sept 8, 2023, to Jan 26, 2024, 409 individuals were screened for eligibility. In total, 243 individuals were randomly assigned to monlunabant 10 mg (n=61), monlunabant 20 mg (n=61), monlunabant 50 mg (n=60), and placebo (n=61); 242 participants received treatment, including 167 (69%) females and 75 (31%) males. 183 (76%) of 242 participants completed the trial: 50 (82%) of 61 received monlunabant 10 mg, 42 (70%) of 60 received monlunabant 20 mg, 34 (57%) of 60 received monlunabant 50 mg, and 57 (93%) of 61 received placebo. At week 16, participants receiving monlunabant showed statistically significant weight loss compared with those receiving placebo (least squares mean difference vs placebo of -6·4 kg [95% CI -8·0 to -4·9] for monlunabant 10 mg, -6·9 kg [-8·5 to -5·3] for monlunabant 20 mg, and -8·0 kg [-9·7 to -6·4] for monlunabant 50 mg). Adverse events were mostly mild to moderate gastrointestinal and psychiatric disorders and were seen in 42 (69%) of 61 participants in the monlunabant 10 mg group, 47 (78%) of 60 participants in the monlunabant 20 mg group, 55 (92%) of 60 participants in the monlunabant 50 mg group, and 42 (69%) of 61 participants in the placebo group. Withdrawals due to adverse events appeared dose-dependent, occurring in eight (13%) participants who received monlunabant 10 mg, 16 (27%) who received monlunabant 20 mg, 25 (42%) who received monlunabant 50 mg, and none who received placebo, driven by nausea, anxiety, diarrhoea, irritability, and sleep disorder. No deaths were reported. INTERPRETATION: Participants receiving monlunabant showed statistically significant and clinically meaningful weight loss compared with those receiving placebo for all tested doses. Only slightly greater weight loss was observed at higher doses, whereas adverse events appeared dose dependent. Further investigation is needed to assess the safety and efficacy of lower doses of monlunabant, to evaluate its potential as a medication for obesity. FUNDING: Inversago Pharma (a Novo Nordisk company).
引用
- Knop FK, Kunos G, Dicker D, et al. Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. Lancet Diabetes Endocrinol. 2025. PMID: 41038215. doi:10.1016/S2213-8587(25)00216-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。